United Therapeutics CFO sells 21,000 shares, up to $439.66

United Therapeutics (UTHR) disclosed that its CFO and Treasurer exercised 21,000 stock options at $146.03 and sold the resulting shares in multiple trades on November 4, 2025 under a Rule 10b5-1 trading plan entered on August 5, 2025.

Rhea-AI Filing Summary

United Therapeutics (UTHR) disclosed that its CFO and Treasurer exercised 21,000 stock options at $146.03 and sold the resulting shares in multiple trades on November 4, 2025 under a Rule 10b5-1 trading plan entered on August 5, 2025.

The sales were executed in blocks at weighted average prices ranging from $432.0874 to $439.5102, covering all 21,000 shares acquired upon exercise. After these transactions, the reporting person directly owned 8,118 shares of common stock.

Insider Trade Summary

Exercise and Sale: 21,000 shares ($6.09M approx. pre-tax spread)

Exercise and Sale 11 txns

Insider EDGEMOND JAMES

Role CFO AND TREASURER

Sold 21,000 shs ($9.16M)

Approx. gross sale proceeds $9.16M

Approx. exercise cost $3.07M

Approx. pre-tax spread $6.09M

Type	Security	Shares	Price	Value
Exercise	Stock Options	21,000	$0.00	$0.00
Exercise	Common Stock	21,000	$146.03	$3.07M
Sale	Common Stock	98	$432.0874	$42K
Sale	Common Stock	1,074	$432.8607	$465K
Sale	Common Stock	1,512	$433.7775	$656K
Sale	Common Stock	1,679	$434.9622	$730K
Sale	Common Stock	6,088	$435.8145	$2.65M
Sale	Common Stock	7,317	$436.7787	$3.20M
Sale	Common Stock	2,752	$437.7406	$1.20M
Sale	Common Stock	360	$438.4986	$158K
Sale	Common Stock	120	$439.5102	$53K

Holdings After Transaction: Stock Options — 31,312 contracts (Direct); Common Stock — 8,118 shares (Direct)

Footnotes (10)

1. F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.
2. F10. This transaction was executed in multiple trades at prices ranging from $439.37 to $439.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F2. This transaction was executed in multiple trades at prices ranging from $431.31 to $432.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F3. This transaction was executed in multiple trades at prices ranging from $432.31 to $433.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. F4. This transaction was executed in multiple trades at prices ranging from $433.31 to $434.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. F5. This transaction was executed in multiple trades at prices ranging from $434.31 to $435.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. F6. This transaction was executed in multiple trades at prices ranging from $435.31 to $436.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. F7. This transaction was executed in multiple trades at prices ranging from $436.31 to $437.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. F8. This transaction was executed in multiple trades at prices ranging from $437.31 to $438.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. F9. This transaction was executed in multiple trades at prices ranging from $438.34 to $438.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did United Therapeutics (UTHR)'s CFO report on Form 4?

He exercised 21,000 stock options at $146.03 and sold the resulting shares on November 4, 2025 under a Rule 10b5-1 plan.

What prices were UTHR shares sold at in the reported transactions?

Sales were executed at weighted average prices from $432.0874 to $439.5102, across multiple trade blocks.

How many UTHR shares does the reporting person hold after the transactions?

Following the reported trades, the reporting person directly owned 8,118 shares.

Were the transactions made under a 10b5-1 trading plan?

Yes. The filing states they were made pursuant to a Rule 10b5-1 plan entered on August 5, 2025.

What role does the reporting person hold at United Therapeutics (UTHR)?

The reporting person is the company’s CFO and Treasurer.

What was the date of the transactions reported on Form 4?

The transactions occurred on November 4, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2025		M(1)		21,000	A	$146.03	29,118	D
Common Stock	11/04/2025		S(1)		98	D	$432.0874(2)	29,020	D
Common Stock	11/04/2025		S(1)		1,074	D	$432.8607(3)	27,946	D
Common Stock	11/04/2025		S(1)		1,512	D	$433.7775(4)	26,434	D
Common Stock	11/04/2025		S(1)		1,679	D	$434.9622(5)	24,755	D
Common Stock	11/04/2025		S(1)		6,088	D	$435.8145(6)	18,667	D
Common Stock	11/04/2025		S(1)		7,317	D	$436.7787(7)	11,350	D
Common Stock	11/04/2025		S(1)		2,752	D	$437.7406(8)	8,598	D
Common Stock	11/04/2025		S(1)		360	D	$438.4986(9)	8,238	D
Common Stock	11/04/2025		S(1)		120	D	$439.5102(10)	8,118	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$146.03	11/04/2025		M(1)			21,000	03/15/2020	03/15/2027	Common Stock	21,000	$0.00	31,312	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $431.31 to $432.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $432.31 to $433.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $433.31 to $434.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $434.31 to $435.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $435.31 to $436.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $436.31 to $437.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $437.31 to $438.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $438.34 to $438.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $439.37 to $439.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.